The colectomy-focused robotic surgical device developer has now assembled $51.7m having spun out from University of Nebraska Medical Center in 2006.

Inserm Transfer Initiative featured in the first round for VectivBio, a short bowel syndrome treatment developer spun out of Therachon following the latter's acquisition by Pfizer.

Novo took part in the first round for VectivBio, a short bowel syndrome treatment developer launched out of genetic disease drug developer Therachon.

The colectomy-focused surgical device developer, which counts SinoPharm as an earlier investor, has secured series B-plus funding, in a round led by Bluestem Capital.

Galecto, whose investors include Novo, Merck Group and Bristol-Myers Squibb, is merging with Celgene-backed PharmAkea, with the joint entity retaining the Galecto name and leadership team.

Novo Seeds returned for a series B round that will support the progress of NorthSea Therapeutics' lead liver disease candidate through clinical trials.

The eye disease drug developer has closed a round led by existing backer Boehringer Ingelheim Venture Fund to take its total funding above $42m.

After five years focusing on life sciences investments for GV, Vineeta Agarwala has taken a general partner role at Andreessen Horowitz.

Paris Descartes University's gene therapy developer has raised $42.1m altogether following a series B featuring existing investors including Inserm Transfert Initiative.

Samsung, SIG and OP Financial contributed to $144m in funding, raised across two rounds, for digital health technology producer Zhiyun Health.